

S3 Table. Risk factors for severe to critical COVID-19 in patients with B-cell lymphoma treated with B-cell depleting agents within 1 year prior to COVID-19

	Severe to critical (n=24)	Non-severe (n=20)	Univariate		Multivariable	
			OR (95% CI)	p-value	aOR (95% CI)	p-value
Age (per 1-year increase)	74 (64-76)	65 (43-71)	1.07 (1.01-1.13)	0.017	1.06 (1.00-1.13)	0.045
Male sex	16 (66.7)	10 (50.0)	2.00 (0.59-6.78)	0.265		
BMI	21.4 (19.3-24.6)	24.4 (22.2-27.3)	0.85 (0.72-1.01)	0.069		
Vaccination status						
Fully vaccinated	17 (70.8)	15 (75.0)	0.81 (0.21-3.10)	0.757		
Underlying comorbidities						
HTN	10 (41.7)	6 (30.0)	1.67 (0.48-5.84)	0.425		
DM	5 (20.8)	4 (20.0)	1.05 (0.24-4.59)	0.946		
CKD	1 (4.2)	1 (5.0)	0.83 (0.05-14.11)	0.895		
CVD	0	1 (5.0)	-	> 0.999		
Chronic lung disease	2 (8.3)	0	-	0.999		
ECOG performance status						
0-1	22 (91.7)	20 (100)	1.00			
≥ 2	2 (8.3)	0	-	0.999		
B-cell depleting therapy						
RTX	13 (54.2)	18 (90.0)	1.00		1.00	
TCE	11 (45.8)	2 (10.0)	7.62 (1.44-40.33)	0.017	5.74 (1.00-32.85)	0.050
Total duration of TCE or RTX therapy	328 (131-404)	137 (36-214)	1.00 (1.00-1.00)	0.485		
Prior lymphoma therapy						
Autologous stem-cell transplant	2 (8.3)	5 (25.0)	0.27 (0.05-1.60)	0.149		
CAR T-cell therapy	0	1 (5.0)	-	> 0.999		
Bendamustine therapy	12 (50.0)	8 (40.0)	1.50 (0.45-4.98)	0.508		
Lymphoma status						
Response ^{a)}	18 (81.8)	13 (76.5)	1.00			
Non-response	4 (18.2)	4 (23.5)	0.72 (0.15-3.43)	0.682		
Dominant variant						
Omicron	23 (95.8)	17 (85.0)	1.00			
Delta	1 (4.2)	3 (15.0)	0.25 (0.02-2.58)	0.242		

Values are presented as median (IQR) or number (%). aOR, adjusted odds ratio; BMI, body mass index; CAR, chimeric antigen receptor; CI, confidence interval; CKD, chronic kidney disease; COVID-19, coronavirus disease 2019; CVD, cardiovascular disease; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; HTN, hypertension; IQR, interquartile range; OR, odds ratio; RTX, rituximab; TCE, T-cell engager. ^{a)}Include complete or partial response to treatment.